IP Library › Granted Patent US 9,018,378
Granted Patent B2
US 9,018,378 · App. 13/946,189 · Granted Apr 28, 2015

Processes and intermediates for preparing fused heterocyclic kinase inhibitors

Inventors: Franck Raeppel (Montreal, CA); Ljubomir Isakovic (Beaconsfield, CA); Stephen William Claridge (Montreal, CA); Michael Mannion (Montreal, CA); Lijie Zhan (Montreal, CA); Marie-Claude Granger (LaPrairie, CA); Arkadii Vaisburg (Kirkland, CA)
Assignee: Methylgene Inc.
C07D495/04C07D213/61C07D213/38C07D213/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,018,378
App. No.
13/946,189
Granted
Apr 28, 2015
Kind
B2
Abstract

This invention relates to intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.

Claims (6)

1. A compound having the structure:

2. A compound having the structure:

3. A compound having the structure:

4. A compound having the structure:

5. A compound having the structure:

6. A compound having the structure:

Assignments (2)
CHANGE OF NAME Recorded Oct 11, 2022
From: METHYLGENE INC.
To: METHYLGENE ULC
Reel/Frame 061375/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2022
From: METHYLGENE ULC
To: MIRATI THERAPEUTICS, INC.
Reel/Frame 061375/0825 →
Continuity (4)
Continuation 13330959 · Dec 20, 2011
Continuation 12231297 · Aug 29, 2008
Provisional Application 60968672 · Aug 29, 2007
Related Publication 20130310564A1 · Nov 21, 2013